Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zandelisib in Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT03768505Phase 2Terminated
- Sponsor
- MEI Pharma
- Start
- Jun 2019
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label, single-arm trial of zandelisib in follicular lymphoma (FL) and marginal zone lymphoma (MZL), sponsored by MEI Pharma. Primary endpoint: Objective Response Rate. Started Jun 2019; status: terminated.
02
Drugs
zandelisib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03768505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768505.